SageView Advisory Group’s Recursion Pharmaceuticals RXRX Stock Holding History

SageView Advisory Group’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$4.09K	Buy	+1,000	New	+$4.95K	﹤0.01%	2025

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

SageView Advisory Group's RXRX Position: Q4 2025 in Review

SageView Advisory Group opened a new position in Recursion Pharmaceuticals (RXRX) in Q4 2025: 1,000 shares worth $4.09K. The stake represents ﹤0.01% of the portfolio and ranks #2025 among its holdings.

333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

SageView Advisory Group held 1,000 shares of Recursion Pharmaceuticals worth $4.09K as of Q4 2025.
Recursion Pharmaceuticals was a new SageView Advisory Group position in Q4 2025.
Recursion Pharmaceuticals made up ﹤0.01% of SageView Advisory Group's portfolio in Q4 2025, its #2025 holding.
333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on SageView Advisory Group's 13F filing for Q4 2025, filed 17 Feb 2026.